[{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2025","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Formosa Pharmaceuticals \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Cipla"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"10","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Cristalia Produtos Quimicos Farma. Ltda","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Medvisis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Medvisis","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Medvisis"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"DAVI Farmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ DAVI Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ DAVI Farmaceutica"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Formosa Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Cipla has rights to market the innovative treatment, APP13007, a novel, patent protected and USFDA approved ophthalmic product, for post-operative inflammation and pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          March 18, 2025

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Cipla

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the license agreement, Medvisis will obtain rights of APP13007 (clobetasol propionate) in Switzerland and Liechtenstein for the post-operative inflammation & pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          November 28, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Medvisis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the term license agreement, DAVI will gain the exclusive rights to commercialize APP13007 (clobetasol propionate) for the treatment of inflammation and pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          October 31, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : DAVI Farmaceutica

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          September 05, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Tabuk Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of dry eye disease.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          July 08, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Eyenovia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          May 08, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of post-operative inflammation and pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          April 03, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : AimMax Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          January 26, 2024

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Cristalia Produtos Quimicos Farma. Ltda

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is und...

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          August 16, 2023

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Eyenovia

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.

                          Product Name : APP13007

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 05, 2023

                          Lead Product(s) : Clobetasol Propionate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : AimMax Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank